Sep 2026
Abstract B107: Peptide-delivered low dose IL-2 reprograms pancreatic cancer immunity to improve survival
Metastatic pancreatic cancer (PC) has a dismal 5-year survival rate of 2% due to limited chemotherapy, lack of immunotherapy options, and high drug resistance. The tumor-immune microenvironment (TIME) in PC, marked by dense desmoplasia, inactive anti-cancer T-cells, and immunosuppressive regulatory T-cells (Tregs...
In Hwan Park, G. Botta, Shawn A. Abeynaike et al.
· Cancer Research · 0 citations